Associate Professor, Oncology, University of Texas Medical School at Houston
Oncology
Dr. Eric Jonasch, MD
|
|
Give Review
Eric Jonasch practices Oncology. He has 3 awards "America's Top Doctors", "Top Doctors:SE Texas" and "America's Top Doctors for Cancer". Eric Jonasch is a published physician. He published 46 publications, including: 'Phosphorylation-dependent cleavage regulates von Hippel Lindau proteostasis and function.' He is registered with Medicare.
Publications
- Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations.
- The radiogenomic risk score stratifies outcomes in a renal cell Cancer phase 2 clinical trial.
- Outcomes of Unselected Patients with Metastatic Clear-Cell Renal Cell Carcinoma Treated with Front-Line Pazopanib Therapy Followed by Vascular Endothelial Growth Facto...
- Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal Cell carcinoma-specific death.
- Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal Cell carcinoma: evidence from a nationwide sample of...
- Surgical Management for Local Retroperitoneal Recurrence Of Renal Cell Carcinoma After Radical Nephrectomy.
- Posttraumatic stress and depressive symptoms in renal Cell carcinoma: association with quality of life and utility of single-item distress screening.
- Clinically nonmetastatic renal Cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent.
- Kidney Cancer, version 3.2015.
- Alternate sunitinib schedules in patients with metastatic renal Cell carcinoma.
- Hypoxia-induced SUMOylation of E3 ligase HAF determines specific activation of HIF2 in clear-Cell renal Cell carcinoma.
- First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Commun...
- Clear cell papillary renal cell carcinoma in patients with von Hippel-Lindau syndrome-clinicopathological features and comparative genomic Analysis of 3 cases.
- Genetic Kidney Cancer Syndromes.
- Comparative effectiveness of second-line targeted therapies for metastatic renal Cell carcinoma: synthesis of findings from two multi-practice chart reviews in the Uni...
- Treatment patterns in metastatic renal Cell carcinoma: a retrospective review of medical records from US community oncology practices.
- Autophagy mediates HIF2α degradation and suppresses Renal tumorigenesis.
- Psychological states, serum markers and survival: associations and predictors of survival in patients with renal Cell carcinoma.
- Genetic and Pharmacological Strategies to Refunctionalize the von Hippel Lindau R167Q Mutant Protein.
- Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial Carcinoma.
- Randomized controlled trial of expressive writing for patients with renal Cell carcinoma.
- Partial nephrectomy in the setting of metastatic renal Cell carcinoma.
- Kidney Cancer, version 2.2014.
- Outcomes of Patients With Metastatic Renal Cell Carcinoma and End-Stage Renal Disease Receiving Dialysis and Targeted Therapies: A Single Institution Experience.
- Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Alternative Sunitinib Schedules.
- mTOR inhibitor associated noninfectious pneumonitis in patients with renal cell Cancer: management, predictors, and outcomes.
- Coordinate phosphorylation of multiple residues on single AKT1 and AKT2 molecules.
- Outcomes of patients with metastatic clear-Cell renal Cell carcinoma treated with pazopanib after disease progression with other targeted therapies.
- Tumor-Specific Isoform Switch of the Fibroblast Growth Factor Receptor 2 Underlies the Mesenchymal and Malignant Phenotypes of Clear Cell Renal Cell Carcinomas.
- DDX3 regulates DNA damage-induced apoptosis and p53 stabilization.
- Radiofrequency ablation of Renal tumours with clinical, radiographical and pathological results.
- Illness Uncertainty and Quality of Life of Patients with Small Renal Tumors Undergoing Watchful Waiting: A 2-year Prospective Study.
- Site-specific activation of AKT protects Cells from death induced by glucose deprivation.
- Contemporary approach to diagnosis and classification of renal Cell carcinoma with mixed histologic features.
- The Impact of Tyrosine Kinase Inhibitors on the Multimodality Treatment of Brain Metastases From Renal Cell Carcinoma.
- Depressive symptoms and cortisol rhythmicity predict survival in patients with renal Cell carcinoma: role of inflammatory signaling.
- Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal Cell carcinoma patients.
- A Phase 2 Trial of Sunitinib in Patients with Advanced Non-clear Cell Renal Cell Carcinoma.
- Phase II Trial of Pemetrexed Plus Gemcitabine in Patients With Locally Advanced and Metastatic Nonclear Cell Renal Cell Carcinoma.
- Agents that stabilize mutated von Hippel-Lindau (VHL) protein: results of a high-throughput screen to identify compounds that modulate VHL proteostasis.
- Pazopanib therapy for cerebellar hemangioblastomas in von Hippel-Lindau disease : Case report.
- Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Linda...
- Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal Cell carcinoma.
- Cadherin-11 in renal Cell carcinoma bone metastasis.
- Phosphorylation-dependent cleavage regulates von Hippel Lindau proteostasis and function.
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- AdRenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors:SE Texas
- America's Top Doctors for Cancer
Education
-
Tufts Medical Center -
McGill University Faculty of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1558457028 | |
| NPPES Provider LastName | JONASCH | |
| NPPES Provider FirstName | ERIC | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 676.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 42.0 | |
| Percent Opioid Claims | 6.21 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1558457028 |
| Last Name Of The Provider | JONASCH |
| First Name Of The Provider | ERIC |
| View All |
Similar Doctors
|
|
Dr. Emil J. Freireich, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Paul Zhang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Polly A. Niravath, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ralph G. Zinner, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Lynne V. Abruzzo, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Julie A. Ellerhorst, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Rashmi K. Murthy, MD |
|
|
Dr. Lijda Vellekoop, MD |
|
|
Dr. Kanwal P. Raghav, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Abdul-Masih F P. Farha, MD |
|
|
Dr. George R. Blumenschein Jr., MD |
|
|
Dr. Michael A. Davies, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bryan T. Hennessy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Faye M. Johnson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Xiaohong I. Wang, MD |
|
|
David T. Kang |
|
Dr. Ajay Mitter, MD
This Doctor is OpenDoctor Recommended.
|